Market Exclusive

Analyst Activity – HC Wainwright Initiates Coverage On Agile Therapeutics (NASDAQ:AGRX) With a Buy

Analyst Ratings For Agile Therapeutics (NASDAQ:AGRX)

Today, HC Wainwright initiated coverage on Agile Therapeutics (NASDAQ:AGRX) with a Buy with a price target of $10.00.

There are 6 buy ratings on the stock.

The current consensus rating on Agile Therapeutics (NASDAQ:AGRX) is Buy (Score: 3.00) with a consensus target price of $11.17 per share, a potential 126.50% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics (NASDAQ:AGRX) has insider ownership of 3.50% and institutional ownership of 79.78%.

Recent Trading Activity for Agile Therapeutics (NASDAQ:AGRX)
Shares of Agile Therapeutics closed the previous trading session at 4.93 up +0.76 18.23% with 553,444 shares trading hands.

Exit mobile version